Share: Facebook Twitter GooglePLus LinkedIn
Activity Provided By:

USF Health and i3 Health

Nursing Strategies to Optimize Treatment Experiences in Hormone-Receptor Positive, HER2-Negative Metastatic Breast Cancer

Access Activity

Overview / Abstract:


Breast cancer accounts for nearly 30% of cancer diagnoses among women in the United States, and is the second-leading cause of cancer death in this population. Although many women benefit from regular screening as well as earlier and improved treatment, approximately 10% present with metastatic disease, and 30% with no initial lymph node involvement eventually develop metastatic disease. Women with metastatic breast cancer (MBC) have a poorer prognosis than the overall population of breast cancer patients, and issues such as refractory or resistant disease, cumulative toxicities, adverse events, depression, and financial hardship are often encountered. Despite progress in understanding the pathogenesis of MBC and advances in therapy, the 5-year overall survival rate remains only 22%.


Oncology nurses, nurse practitioners, clinical nurse specialists, and other health care professionals involved in the management of patients with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer.


Upon completion of this activity, participants should be able to:

1. Describe patient- and disease-related factors that can inform individualized treatment planning in HR-positive, HER2-negative MBC
2. Differentiate therapeutic and safety profiles of CDK4/6 inhibitors in HR-positive, HER2-negative MBC
3. Apply supportive care strategies to mitigate adverse events associated with CDK4/6 inhibitors and promote adherence to therapy


Sep 30, 2019


Nurse Practitioner , Nursing CNE


Online, Webinar / Webcast / Video

Credits / Hours




Presenters / Authors / Faculty

Constance Visovsky, PhD, RN, ACNP, FAAN
Associate Professor, College of Nursing
University of South Florida

Sponsors / Supporters / Grant Providers

This activity is supported by an independent educational grant from Lilly.

Keywords / Search Terms

i3 Health i3 Health, breast cancer, metastatic breast cancer, MBC, HR-positive, CDK4/6 inhibitors, oncology, CE, free CE, online CE Free CE CME

Access Activity

RXinsider,, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the website or within our mobile apps. RXinsider,, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or or within our mobile apps. For complete details, please read the Terms of Service. Site Map.